Leonard S. Schleifer
M.D., Ph.D.Board co-Chair, President and Chief Executive Officer
Regeneron Pharmaceuticals, Inc. · REGN
$7.3M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A filed April 24, 2026. Prior years are from that filing's three-year table.
Catalog as of September 15, 2026. Not a live market feed.
- Salary
- $2M
- Incentives
- $3.7M
- Other
- $1.6M
Compensation History
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $1,979,922 | $0 | $7,280,549 |
| 2024 | $1,941,100 | $0 | $6,823,034 |
| 2023 | $1,875,415 | $0 | $8,184,338 |
Current Position
- Title
- M.D., Ph.D.Board co-Chair, President and Chief Executive Officer
- Ticker
- REGN · NASDAQ
- Fiscal Year
- 2025
SEC Sources
Fiscal years below are columns from the latest DEF 14A Summary Compensation Table (filed April 24, 2026), not separate historical filings.
| Fiscal Year | Source |
|---|---|
| 2025 | View SEC filing |
| 2024 | View SEC filing |
| 2023 | View SEC filing |
Accession 0001308179-26-000340.
Other Regeneron Executives
George D. Yancopoulos
M.D., Ph.d.board Co-Chair, President And Chief Scientific Officer
Regeneron · REGN
$6.9M
FY 2025 · DEF 14A
Christopher Fenimore
Executive Vice President, Finance And Chief Financial Officer
Regeneron · REGN
$7M
FY 2025 · DEF 14A
Daniel P. Van Plew
Executive Vice President And General Manager, Industrial Operations And Product Supply
Regeneron · REGN
$8.8M
FY 2025 · DEF 14A
Andrew J. Murphy
Ph.d.executive Vice President, Co-Chief Scientific Officer
Regeneron · REGN
$8.5M
FY 2025 · DEF 14A
Joseph J. La Rosa
Executive Vice President, General Counsel And Secretary10
Regeneron · REGN
$7.5M
FY 2025 · DEF 14A